Federal Equity Rules

RiskOn International Confirms It Has Appealed Nasdaq’s Delisting Letter

Retrieved on:

Monday, December 11, 2023

Technology, Finance, Fintech, Professional Services, Metaverse, Blockchain, Software, Data Management, Web3, Federal Equity Rules, Form, Equity, Staff, File, Delisting, Hearing, Panel, Financial adviser

RiskOn International, Inc. (Nasdaq: ROI) (“RiskOn,” or the “Company”), today announced that it filed an appeal to the Delisting Letter (“Letter”) received on December 1, 2023 from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”).

Key Points:

RiskOn International, Inc. (Nasdaq: ROI) (“RiskOn,” or the “Company”), today announced that it filed an appeal to the Delisting Letter (“Letter”) received on December 1, 2023 from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”).
The Company submitted a plan of compliance to Nasdaq to regain compliance with the Equity Rule the (“Compliance Plan”), which the Company subsequently revised, detailing the actions the Company would take to regain compliance with the Equity Rule.
On December 8, 2023, the Company requested a hearing (the “Hearing”) before the Nasdaq Listing Qualifications Panel (“Panel”) to appeal the determination by the Staff.
At the Hearing, the Company must demonstrate its ability to regain compliance with the Equity Rule, as well as its ability to sustain long-term compliance with all applicable maintenance criteria.

AnPac Bio-Medical Science Granted Continued Listing by NASDAQ Hearing Panel, Subject to Meeting the Equity Rule on or before July 12, 2023

Retrieved on:

Thursday, March 23, 2023

Capital market, Federal Equity Rules, American depositary receipt, Sale, Panel, Acquisition, Hearing, Equity capital markets, Staff, Letter, Financial adviser

The Panel advised that July 12, 2023, represents the full extent of the Panel's discretion to grant continued listing while the Company is non-compliant.

Key Points:

The Panel advised that July 12, 2023, represents the full extent of the Panel's discretion to grant continued listing while the Company is non-compliant.
The Panel noted that the Company indicated that while it has already cured the shareholder equity deficiency, it plans to continue engaging in fund-raising activities throughout the year to maintain its shareholder equity value.
The Panel indicated that it believes the Company has articulated a reasonable plan and should be afforded time to implement this new strategy.
The Company timely requested a hearing, which stayed any delisting or suspension action relating to the Company's American Depositary Shares through the hearing, which took place in March.,

Smart for Life Provides an Update on Nasdaq Listing

Retrieved on:

Wednesday, February 1, 2023

Wellness, Panel, Cookie, Federal Equity Rules, BID, Acquisition, Hearing, Listing Rules, Health, Ministry of Health & Wellness, News

As previously disclosed, on December 5, 2022, the Company requested a hearing with the Panel, which was held on January 19, 2023.

Key Points:

As previously disclosed, on December 5, 2022, the Company requested a hearing with the Panel, which was held on January 19, 2023.
As a result of the Panel’s decision, the Company now has until May 30, 2023 to regain compliance with the Equity Rule and the Bid Price Rule.
“We are very pleased with the Panel’s decision to grant us an extension to regain compliance,” stated Darren Minton, Smart for Life’s Chief Executive Officer.
“We are continuing to implement our high-growth acquisition strategy and have several potential acquisitions in the pipeline.

AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request A Hearing

Retrieved on:

Friday, January 20, 2023

American depositary receipt, Federal Equity Rules, Hearing, Panel, Pharmaceutical industry, Audit, Property management

Accordingly, the Company intends to timely request a hearing.

Key Points:

Accordingly, the Company intends to timely request a hearing.
The hearing request will automatically stay any delisting or suspension action relating to the Company’s American Depositary Shares through the hearing and the expiration of any additional extension period granted by the Panel following the hearing.
At the hearing, the Company intends to present a plan to achieve and sustain compliance with the Equity Rule and all applicable requirements for continued listing and to request an extension of time within which to complete its compliance plan.
However, there can be no assurance that the Panel will grant the Company’s request for a further extension or that the Company will ultimately regain compliance with all applicable requirements for continued listing.

Ryan Baker Promoted to Vice President at Douglas Wilson Companies

Retrieved on:

Tuesday, January 11, 2022

Douglas Wilson Companies (DWC) today announced that Ryan C. Baker has been promoted to vice president of the firm, where he will continue to lead the Fiduciary Practice.

Key Points:

Douglas Wilson Companies (DWC) today announced that Ryan C. Baker has been promoted to vice president of the firm, where he will continue to lead the Fiduciary Practice.
Ryan is a rising star in receivership with the perfect combination of professional credibility, experience and education, said Douglas Wilson, CEO and chairman of the board of DWC.
Ryan earned a bachelors degree in economics from New York University and an MBA from the University of Southern California.
With its roots in the development business, Douglas Wilson Companies was founded in 1989 after completing the iconic Symphony Towers mixed-use city block in downtown San Diego.